Delcath Systems (DCTH) stock

Liver cancer treatment , market cap $503M

Treatment for liver cancers

Worth $503M

$21.56

+6.36%

As of 11:01 AM ET, delayed 15+ min · Live for Pro members

Quality Score

Exceptional

In its industry

#1of 84

Medical Devices

Checks firing

9of 14

Trending up

From 52-week high

-1.3%

under its best in a year

DCTH's Quality Score rose 1 point on Tue, Nov 10, to 24.

See DCTH's 14 chart checksSee it live, free for 24 hours. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Why is DCTH up?

Up 54% so far from Oct 30 to Nov 10.

Delcath Systems rose 54% so far from Oct 30 to Nov 10. 38 points of it came on Nov 9, the day of its results.

Sources: Price history, Nov 10, 2026; SEC filing, Nov 9, 2026

1 more reason, free with an account →4 more reasons why DCTH is up 54% since Oct 30, from its filings, with the timeline and its peers, for Pro members.

Key facts on DCTH

Key facts on DCTH
Outperforming	Up 150% in a year vs the S&P's +11%
Latest filing	8-K, Nov 9 Reported its quarterly results

1 more reason behind DCTH's 24, free with an account →4 more reasons behind DCTH's 24, for Pro members.

DCTH in the news

ReportYesterday morning: the results are out. Raised its outlook for the year. Past reports ›

YesterdayDelcath Systems Inc (DCTH) (Q3 2026) Earnings Call Highlights: Record Revenue, Raised Guidance ... Yahoo Finance

What's next

Tue Nov 10: UBS Global Healthcare Conference 2026Investor conference · date confirmed.

2 more dates ahead: conferences, for Pro members.

DCTH catalysts

Coming up

After its last 4 reports it closed +11.6% on average, higher 2 of 4 times.

Why DCTH scores 24

Exceptionalfor quality, not price, 9 of 14 chart checks firingWhat the Quality Score means

Well above its recent run. DCTH scores 24 today, against a median of 10 over its last 20 recorded sessions.

+9Chart checks 9 of 14 firing right now, one point each
+4Long-term trend above a rising 200-⁠day average, near its 52-⁠week high, at a multi-⁠year high

Run-up adds
Profit addsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Growth addsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.
Persistence adds
News adds

No effect today: Size, Dilution, Volatility, and Cash flow.

What every line is worth, and the reason behind it, on DCTH and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 11:01 AM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when DCTH's Quality Score turns up

A free account. No card.

How DCTH ranks in Medical Devices

DCTH is #1 of 84 by Quality Score.

How DCTH ranks in Medical Devices
Rank	Stock	Checks	Quality Score
1	DCTHDelcath Systems	9/14	24
2	EWEdwards Lifesciences	8/14	20
3	LIVNLivaNova	7/14	19
	CNXUConexeu Sciences		Open for its score
	COOThe Cooper Companies		Open for its score
	DRTSAlpha Tau Medical		Open for its score
	DXCMDexCom		Open for its score

When does DCTH report earnings, and what happens after?

Expected to report Thu Feb 25, before the open (in 107 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What DCTH reported on Nov 9, 2026

The quarter

The figures are not read from the release yet.

“The increase is primarily due to increased clinical headcount and increased clinical trial activity.”

The filing on EDGAR

Where the sales came from

DCTH's results filing gives no sales by line in a table we read.

The outlook

The outlook the company gave, by period
Measure	Figure
FY2026
Total HEPZATO KIT and CHEMOSAT revenue	$115M to $117Mraised

Figures as filed (SEC filing, Nov 9)

1 more outlook line, for Pro members.

In the company's words

“The increase is primarily due to continued commercial expansion activities.”

From its results filing (SEC filing · Nov 9)

The numbers

Market value: $503M; today
Sales: $110M; up 38.1% on the year
Free cash flow: $20.1M; last 12 months

4 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on DCTH: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

-0.2%+22.5%+35.8%

May 7Aug 6Nov 9

Reported	When	Gap	Reaction	5 days
Nov 9, 2026Before open	Before open	+24.4%	+35.8%	not yet
Aug 6, 2026Before open	Before open	+11.1%	+22.5%	+35.5%
May 7, 2026Before open	Before open	+2.2%	-0.2%	+3.1%

DCTH closed higher after 2 of its last 4 reports.

All 4 reports, and DCTH's Quality Score going into each

DCTH sales and profit by year

Sales and profit by year

Sales grew in two of the last four years, to $85.2M in 2025. It turned a profit in 2025 after a loss in 2024.

DCTH has 9 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on DCTH, and all 14 on every stock.Get in free →

DCTH RSI today: 82.1, above its 50-day and 200-day averages

Not scored

RSI 82.1, MACD above signal, above both averages. Not scored.13 readings

The deep dive on DCTH

What it does and how it makes money5 findingsIt kept 1 cents of each dollar of sales in fiscal 2025: $660K of operating profit on $85.2M of sales.Annual report, filed Feb 26, 2026"In October 2023, after receiving FDA approval for the HEPZATO KIT ® , we requested an extension of the term for one of our patents." (10-K for fiscal 2025)SEC filing · Feb 26, 2026
Where it stands2 findingsFor Pro members2 findings on where DCTH stands: its cash, debt, and share count, for Pro members
What changed in its filings2 findings"On December 16, 2021, the Company initiated an arbitration proceeding pursuant to the dispute resolution procedures of the medac Agreement for the non-payment of the invoice." (10-Q for the quarter to Sep 30, 2026)SEC filing · Nov 9, 2026One customer made up 15% of its revenue in fiscal 2025, down from 20% in fiscal 2024.SEC filing · Feb 26, 2026
Who holds and trades it1 findingFor Pro members1 finding on who holds and trades DCTH, for Pro members

6 more findings on DCTH, each with its source, for Pro members.

DCTH's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Gerard J. MichelChief Executive Officer · 2 trades
Sandra PennellChief Financial Officer · 1 trade
John Richard SylvesterDirector · 1 trade
Gil AharonDirector · no trades on file
Steven A. J. SalamonDirector · no trades on file

See insider trades by person

Which ETFs hold DCTH?

In ETFs: DCTH is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Delcath Systems

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

156 employeesQueensbury, NYdelcath.com

What Delcath Systems says it competes with

“The healthcare industry is characterized by extensive research, rapid technological progress and significant competition from numerous healthcare companies and academic institutions.”

From its annual report, SEC filing · Feb 26, 2026

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on DCTH and every other stock.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would move DCTH's score: 2 things
2 more filings explained, a plain line each
Real-⁠time prices, no delay

See DCTH's 14 chart checks

See it live, free for 24 hours. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 10, 2026: DCTH's Quality Score is 24 (Exceptional), #1 of 84 in Medical Devices.

What does DCTH's Quality Score say?

DCTH scores 24 today, which Breakaway calls Exceptional. It is #1 of 84 in Medical Devices by Quality Score, with 9 of 14 chart checks firing. Up 54% so far from Oct 30 to Nov 10. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is DCTH's Quality Score?

DCTH scores 24 today, which Breakaway calls Exceptional (20 or more). That is #1 of 84 in Medical Devices by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind DCTH's 24.

When does DCTH report earnings?

Expected to report Thu Feb 25, before the open, a date Breakaway expects from the company's usual timing; the company has not confirmed it. DCTH closed higher after 2 of its last 4 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.